These findings highlight the limitations of both CHA2DS2-VASc and CHA2DS2-VA in risk stratification for intermediate-risk AF patients and suggest that biomarker-enhanced models such as hs-cTnT could improve risk assessment in clinical routine. The gene discussed is TNNT2; the disease is atrial fibrillation.